MeiraGTx Holdings PLC is a clinical-stage gene therapy company headquartered in New York, dedicated to developing groundbreaking treatments for severe genetic disorders. Leveraging cutting-edge gene-editing technologies, the company targets significant unmet medical needs in therapeutic areas such as ophthalmology, neurology, and rare diseases. With a robust and diversified pipeline, MeiraGTx is poised to become a frontrunner in the field of genetic medicine, aiming to transform the landscape of patient care through its innovative therapeutic solutions.